Introduce a Lymphedema Prevention Program

Prevent Cancer-Related Lymphedema with Early Detection & Treatment Protocol

Lymphedema is one of the most feared consequences of cancer treatment among survivors1. Early detection is critical to preventing lymphedema from becoming a chronic condition. SOZO® with L-Dex® helps healthcare professionals to identify at-risk patients early and intervene before lymphedema becomes irreversible.

Lymphedema Prevention Program Logo

50% of patients who develop Lymphedema do so within 1 year after surgery2

Pat Whitworth, M.D. & Laura Lawson, M.D. Discuss Lymphedema Prevention

Dr. Pat Whitworth, Surgical Oncologist/Director and Dr. Laura Lawson, Breast Surgery Specialist, from the Nashville Breast Center share how their prevention protocol, aided by SOZO® with L-Dex®, has improved the treatment and prevention of lymphedema.

Bioimpedance Spectroscopy (BIS) Clinical Evidence

ImpediMed’s L-Dex® technology has demonstrated real-world lymphedema-related outcomes as published in more than 140 peer-reviewed studies on over 17,000 patients. Our BIS technology is backed by over 400 peer-reviewed journal articles across a number of chronic diseases.

Direct Fluid Measurement (L-Dex®) vs. Indirect Fluid Measurement

Traditional measurement tools are rudimentary and unreliable, or prohibitively expensive, complicated and invasive. Perometry, along with such low-tech tools like tape measure and water displacement, cannot measure an increase in fluid until actual swelling exists – the point where lymphedema may be irreversible.

SOZO® measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz to provide a detailed fluid and tissue analysis. 

Immediately Access & Share Data Across Your Healthcare System

SOZO® allows medical staff in hospitals and cancer clinics to test patients at the point of care and immediately share that information with oncologists and nurse practitioners.

Guidelines for Lymphedema Prevention

Test. Trigger. Treat.TM
While it is not possible to predict which patients will develop lymphedema, the L-Dex® score was shown to detect the accumulation of fluid due to lymphedema early enough to treat and prevent progression5.


Set an L-Dex® Baseline & Initiate Periodic Testing After Surgery

Once a patient has been diagnosed with breast cancer, melanoma, or pelvic area cancers, they will be tested by a staff member to record a baseline L-Dex® score. After cancer surgery, it is recommended that patients get tested every 3 months for the first 3 years, every 6 months for years 4 and 5, and annually thereafter6.


Evaluate Increases 6.5 Above L-Dex® Baseline

Clinical evidence supports that an elevated L-Dex® score of 6.5 or more from the baseline serves as a “trigger” to indicate that the patient should be evaluated and treatment intervention should begin5.


Apply Treatment Protocol to Reduce Lymphedema Progression

Treatment for patients diagnosed with early lymphedema, including standard compression garments worn at home for 4 weeks, 12 hours per day, has been shown to reduce the progression of lymphedema by 95% in breast cancer patients5.

SOZO® with L-Dex® Helps Detect Lymphedema at the Subclinical Level

Bioimpedance spectroscopy (BIS) is the only reliable, non-invasive tool that can accurately detect accumulation of fluid due to subclinical lymphedema. In less than 30 seconds, medical staff can record an L-Dex® score or fluid status and tissue composition using SOZO®.

Introduce a Lymphedema Prevention Program

Discover how to help patients avoid chronic lymphedema by introducing a Lymphedema Prevention Program.

Together, We Can End Cancer-Related Lymphedema

Contact us to learn about SOZO® with L-Dex® and the benefits of supporting a Lymphedema Prevention Program.


  1. Accessed September 12, 2019.
  2. Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019;
  3. American Cancer Society’s Cancer Facts and Figures, 2019.
  4. Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema.  CA Cancer J Clin. 2015;00:00–00.
  5. Brown JC, et al. The Prevalence of Lymphedema Symptoms among Long-Term Cancer Survivors with or at-risk for Lower Limb Lymphedema. Am J Phys Med Rehabil. 2013 March ; 92(3): 223–231. doi:10.1097/PHM.0b013e31826edd97.
  6. Herd-Smith, A., et al., Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer, 2001.  92(7): p. 1783-7

General or Sales Inquiries
1 +61-7-3860-3700

U.S. Headquarters

5900 Pasteur Ct.
Ste. 125
Carlsbad, CA 92008 USA

+1-877-BIS-0111 or
+1-877-247-0111 (Toll Free)
Phone: +1-760-585-2100 
Fax: +1-760-804-9245

European Office

Registered Office

Unit 1
50 Parker Court
Pinkenba, QLD 4008 Australia

Phone: + 61-7-3860-3700
Fax: + 61-7-3260-1225
Free call: 1-800-638-477